Publication date: Nov 26, 2019
Asuragen, Inc. , a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, and Wave Life Sciences, a clinical-stage genetic medicines company developing life-changing treatments for people battling devastating diseases, have entered into an agreement for the development and commercialization of companion diagnostics for Wave’s investigational allele-selective therapeutic programs targeting Huntington’s disease (HD).
The companion diagnostics that Asuragen will develop build on the experience gained by Wave using a single-nucleotide polymorphism (SNP) phasing methodology in Wave’s current clinical trials in HD and a previous observational study.
-Our partnership with Asuragen for companion diagnostic development was a natural fit in light of their deep knowledge and expertise with challenging molecular targets, diagnostic regulatory experience and their growing presence in the neurogenetics testing market,” said Jaya Goyal, Ph. D., Vice President of Bioanalytics, Pharmacology, and Biomarker Development at Wave Life Sciences.
Asuragen will leverage this technology to develop companion diagnostic tests that size and phase HTT CAG repeats with two different SNPs targeted by Wave’s WVE-120101 and WVE-120102 investigational therapeutic programs.
Developing a companion diagnostic for Wave’s novel allele-selective silencing program in HD is a great example of how our products will continue to advance personalized medicine,” said Matthew McManus, M. D., Ph. D. president and CEO of Asuragen.